Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03176303 · ClinicalTrials.gov registry record
Study Using the SpinalStim Device Following Lumbar Fusion Surgery
A clinical trial, sponsored by Orthofix.
- Completed
- Registry status
- 206
- Enrollment target
NCT03176303: Completed study, sponsored by Orthofix.
NCT03176303 is a clinical trial that has completed, run by Orthofix. The registered enrollment target is 206 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03176303 has completed, sponsored by Orthofix.
- COMPLETED
- Registry status
- 206 participants
- Enrollment target
Study Summary
This study examines the effect of adjunctive use of the SpinalStim bone growth stimulator on lumbar fusion rate in high risk subjects who have had lumbar fusion surgery. All participants will wear the bone growth stimulator for a minimum of 2 hours/day for 6 months.
Primary Outcome
number of subjects with fused lumbar vertebrae, determined by X-rays and CT scans
Interventions
- DEVICE SpinalStim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2017-06-28 |
| Est. Completion | 2021-07-12 |
What the finished NCT03176303 record still lists
NCT03176303 is an observational study that tracks outcomes without assigning an intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which SpinalStim is the first listed.
NCT03176303 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03176303 about?
NCT03176303 is a clinical study titled "Study Using the SpinalStim Device Following Lumbar Fusion Surgery". This study examines the effect of adjunctive use of the SpinalStim bone growth stimulator on lumbar fusion rate in high risk subjects who have had lumbar fusion surgery. All participants will wear the bone growth stimulator for a minimum of 2 hours/day for 6 months.
What is the current status of trial NCT03176303?
This trial is currently completed. The enrollment target is 206 participants. The study started on 2017-06-28. Estimated completion is 2021-07-12.
What interventions are being tested in trial NCT03176303?
The interventions under investigation include: SpinalStim (DEVICE).
Who is sponsoring clinical trial NCT03176303?
This trial is sponsored by Orthofix, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03373968 · 206 participants · Phase 2
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- NCT03550391 · 206 participants · Phase 3
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- NCT04757116 · 206 participants · NA
Post-Market Study to Assess iTind Safety in Comparison to UroLift
- NCT05675865 · 206 participants · NA
Cryoablation for Monomorphic Ventricular Tachycardia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI